Drug shortages are becoming commonplace in the U.S. Data from a new pharmaceutical industry tracking firm, Qyobo, shows hundreds of drugs are still in short supply – some well over a year — and our dependence on imports grows, including from labs on the receiving end of lackluster FDA inspections.
When drugs are pulled from pharmacy shelves, it’s somewhat of a well-kept secret that it is the pharmaceutical company that voluntarily warns buyers of the potential harm from the defect.
Generic drug exporter Zydus Lifesciences received poor marks again in April following a Food and Drug Administration inspection of its lab in Vadodara, a city in Gujarat state on India’s western coast.
The balance between scarcity and supply favors supply, even if that means importing drugs from labs the FDA has not inspected.
The Congressional-Executive Commission on China hears testimony about Zero Covid and the human rights abuses its exacerbated in the world’s No. 2 economy. In a report by the Commission, calls for more capital market sanctions.
The FDA Safety and Landmark Advancements (FDASLA) Act has passed a key committee, with 25 out of some 30 amendments passing. Generics and baby formula crisis got most of the attention.
The Food and Drug Administration recently updated its drug shortage list. More than half of the updates include drugs on the essential medicines list.
Senator Burr warned the FDA that until the Senate is okay with their response to the infant formula crisis, and present a plan to prevent it in the future, the Generic Drug User Fee Authorization bill might be put on hold.
